ArticleDrug design, development and therapy2020

Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.

Liya Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.